74578-69-1
Name | Ceftriaxone sodium |
CAS | 74578-69-1 |
EINECS(EC#) | 277-930-0 |
Molecular Formula | C18H18N8O7S3 |
MDL Number | MFCD00865013 |
Molecular Weight | 554.58 |
MOL File | 74578-69-1.mol |
Synonyms
CEFATRIAXONE
CEFTRIAXONE
2,5,6-tetrahydro-2-methyl-5,6-dioxo-)(methoxyimino)acetyl)amino)-8-oxo-3-(((
4-triazin-3-yl)thio)methyl)-,sodiumsalt,hydrate(2:4:7)(6r-(6-alpha,7-2
beta(z)))-
cefatriaxonehydrate
cephtriaxone
ro13-9904
rocephin
x13-9904
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, disodium salt, [6R-[6alpha,7beta(Z)]]-
CEFTRIAXONE SODIUM, USP
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, disodium salt, [6R-[6α,7β(Z)]]-
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, disodium salt, (6R,7R)-
Ceftriaxone disodium
Longaceph
Ceftriaxonesodiumnon-steriled
[6R-[6alpha,7beta(Z)]]-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid sodium salt
Chemical Properties
storage temp. | 4°C, protect from light |
solubility | Soluble in DMSO (50 mM) |
form | Solid |
color | White to off-white |
Water Solubility | Water : ≥ 40 mg/mL (66.60 mM) |
InChIKey | CDCJSJLFRBHEHN-ZZKDXJNYNA-N |
SMILES | C(C1=C(CS[C@]2([H])[C@H](NC(=O)/C(/C3N=C(N)SC=3)=N\OC)C(=O)N12)CSC1=NC(=O)C(=O)NN1C)(=O)O.[NaH] |&1:5,7,r| |
CAS DataBase Reference | 74578-69-1(CAS DataBase Reference) |
Hazard Information
Hazard
Moderately toxic. Low toxicity by inges-
tion. Human systemic effects.
Description
Ceftriaxone is a cephalosporin (SEF a low spor in) antibiotic that is used to treat conditions such as lower respiratory tract infections, skin and skin structure infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, and meningitis.
Originator
Rocephin,Roche,Switz.,1982
Uses
Ceftriaxone sodium is antibacteria.
Manufacturing Process
19 g of (6R,7R)-7-[2-[2-(2-chloroacetamido)-4-thiazolyl]-2-(methoxyimino)
acetamido]-8-oxo-3-[[(1,4,5,6-tetrahydro-4-methyl-5,6-dioxo-as-triazin-3-
yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid are
suspended in 150 ml of water together with 9.5 g of thiourea. The pH is
adjusted to 6.8 with 5% sodium hydrogen carbonate solution while gassing
with nitrogen and stirring, there being obtained a yellow-orange solution. The
pH of the solution is held constant at 6.8-7.0 for 6 hours by adding sodium
hydrogen carbonate solution by means of an autotitrator. 100% formic acid is
added to the orange colored solution until the pH is 3.5. The precipitated
material is filtered off under suction and washed with 100 ml of 10% formic
acid. This material is denoted as (1). The filtrate is adjusted to pH 2.5 by
adding 100% formic acid, whereby additional substance precipitates out. The
mixture is held in an ice-bath for 1 hour, the precipitated substance is then
filtered off and washed with a small amount of ice-water. This material is
denoted as fraction I. The aforementioned orange-brown material (1) is
suspended in 250 ml of water. The suspension is adjusted to pH 7 with 2 N
sodium hydroxide, there being obtained an orange-brown solution. Additional
100% formic acid is added to this solution until the pH is 3.5. The material which thereby precipitates out is filtered off under suction and discarded. The
filtrate is adjusted to pH 2.5 with 100% formic acid, whereby additional
substance precipitates out. The mixture is held in an ice-bath for 1 hour, the
precipitated substance is then filtered off under suction and washed with a
small amount of ice-water. This material is denoted as fraction II. Fractions I
and II are suspended together in 500 ml of ethanol and evaporated in a
rotary evaporator in order to remove water. After adding ether, the mixture is
filtered under suction and the precipitate is washed successively with ether
and low-boiling petroleum ether. There is thus obtained the title substance in
the form of a yellowish solid material which is denoted as A.
The mother liquors and washings of fractions I and II are concentrated from a volume of about 1.7 liters to 250 ml, the pH is adjusted to 2.5 with 100% formic acid and the solution is stored overnight in a refrigerator, whereby further substance crystallizes. This is filtered off under suction and washed with a small amount of water. The residue on the suction filter is azeotropically distilled with ethanol. There is obtained solid, almost colorless title substance which is denoted as B. B is purer than A according to thin-layer chromatography.
In order to obtain pure title substance, the acid B is suspended in 150 ml of methanol and treated while stirring with 10 ml of a 2 N solution of the sodium salt of 2-ethylcaproic acid in ethyl acetate. After about 10 minutes, there results a solution which is treated with 100 ml of ethanol. The mixture is extensively concentrated at 40°C in vacuo. The sodium salt precipitates out in amorphous form after adding ethanol. This salt is filtered off under suction, washed successively with ethanol and low-boiling petroleum ether and dried at 40°C in a high vacuum. There is obtained the title substance in the form of an almost colorless amorphous powder.
The mother liquors and washings of fractions I and II are concentrated from a volume of about 1.7 liters to 250 ml, the pH is adjusted to 2.5 with 100% formic acid and the solution is stored overnight in a refrigerator, whereby further substance crystallizes. This is filtered off under suction and washed with a small amount of water. The residue on the suction filter is azeotropically distilled with ethanol. There is obtained solid, almost colorless title substance which is denoted as B. B is purer than A according to thin-layer chromatography.
In order to obtain pure title substance, the acid B is suspended in 150 ml of methanol and treated while stirring with 10 ml of a 2 N solution of the sodium salt of 2-ethylcaproic acid in ethyl acetate. After about 10 minutes, there results a solution which is treated with 100 ml of ethanol. The mixture is extensively concentrated at 40°C in vacuo. The sodium salt precipitates out in amorphous form after adding ethanol. This salt is filtered off under suction, washed successively with ethanol and low-boiling petroleum ether and dried at 40°C in a high vacuum. There is obtained the title substance in the form of an almost colorless amorphous powder.
Brand name
Rocephin (Roche).
Therapeutic Function
Antibacterial
General Description
Ceftriaxone was synthesized by HoffmannLa Roche in 1981. The triazinyl moiety was introduced at the 3 position of the cephem nucleus. The same side chain as possessed by cefotaxime and the other so-called third-generation cephalosporins was retained at the 7 position. The antibacterial activity of ceftiaxone is almost the same as that of cefotaxime in vitro, but its in vivo activity is 10 to 100 times higher. Its most characteristic property is its seven to eight hour half-life in serum, the longest among the known cephem antibiotics.
Mechanism of action
Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lac- tamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The β-lactam core of ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell wall synthesis and cell division. By binding to these enzymes, ceftriaxone causes formation of defective cell walls and promotes cell death[1].
Clinical Use
Ceftriaxone sodium is a β-lactamase–resistantcephalosporin with an extremely long serum half-life.Once-daily dosing suffices for most indications. Two factorscontribute to the prolonged duration of action ofceftriaxone: high protein binding in the plasma and slowurinary excretion. Ceftriaxone is excreted in both the bileand the urine. Its urinary excretion is not affected byprobenecid. Despite its comparatively low volume ofdistribution, it reaches the cerebrospinal fluid in concentrationsthat are effective in meningitis. Nonlinear pharmacokineticsare observed.
Ceftriaxone contains a highly acidic heterocyclic systemon the 3-thiomethyl group. This unusual dioxotriazine ringsystem is believed to confer the unique pharmacokineticproperties of this agent. Ceftriaxone has been associatedwith sonographically detected “sludge,” or pseudolithiasis,in the gallbladder and common bile duct. Symptoms ofcholecystitis may occur in susceptible patients, especiallythose on prolonged or high-dose ceftriaxone therapy. Theculprit has been identified as the calcium chelate.
Ceftriaxone exhibits excellent broad-spectrum antibacterialactivity against both Gram-positive and Gram-negativeorganisms. It is highly resistant to most chromosomally andplasmid-mediated β-lactamases. The activity of ceftriaxoneagainst Enterobacter, Citrobacter, Serratia, indole-positiveProteus, and Pseudomonas spp. is particularly impressive. Itis also effective in the treatment of ampicillin-resistant gonorrheaand H. influenzae infections but generally less activethan cefotaxime against Gram-positive bacteria and B.fragilis.
Ceftriaxone contains a highly acidic heterocyclic systemon the 3-thiomethyl group. This unusual dioxotriazine ringsystem is believed to confer the unique pharmacokineticproperties of this agent. Ceftriaxone has been associatedwith sonographically detected “sludge,” or pseudolithiasis,in the gallbladder and common bile duct. Symptoms ofcholecystitis may occur in susceptible patients, especiallythose on prolonged or high-dose ceftriaxone therapy. Theculprit has been identified as the calcium chelate.
Ceftriaxone exhibits excellent broad-spectrum antibacterialactivity against both Gram-positive and Gram-negativeorganisms. It is highly resistant to most chromosomally andplasmid-mediated β-lactamases. The activity of ceftriaxoneagainst Enterobacter, Citrobacter, Serratia, indole-positiveProteus, and Pseudomonas spp. is particularly impressive. Itis also effective in the treatment of ampicillin-resistant gonorrheaand H. influenzae infections but generally less activethan cefotaxime against Gram-positive bacteria and B.fragilis.
Side effects
Ceftriaxone sodium is a bactericidal agent that acts by inhibition of bacterial cell
wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and
Gram-positive bacteria.
Side effects
Common side effects of Ceftriaxone sodium include:
symptoms of a blood cell disorder;
diarrhea;
vaginal itching or discharge;
warmth, tight feeling, or a hard lump where the injection was given;
rash;
abnormal liver function tests.
symptoms of a blood cell disorder;
diarrhea;
vaginal itching or discharge;
warmth, tight feeling, or a hard lump where the injection was given;
rash;
abnormal liver function tests.
Synthesis
A solution of sodium-2-ethyl hexanoate (390 g) in acetone (2.0 Ltr) is added to the wet Ceftriaxone acid obtained in Example 2 is suspended in a mixture of acetone and water. The reaction mixture is charcoalized and filtered. To the clear filtrate is added acetone whereupon the product precipitated. The precipitated solid is filtered, washed with acetone and dried to get 515 g of Ceftriaxone sodium hemiheptahydrate. HPLC purity = Above 99.5%.
Veterinary Drugs and Treatments
Ceftriaxone is used to treat serious infections, particularly against
susceptible Enterobacteriaceae that are not susceptible to other less
expensive agents or when aminoglycosides are not indicated (due
to their potential toxicity). Its long half life, good CNS penetration,
and activity
against Borrelia burgdorferi also has made it a potential
choice for treating Lyme’s disease.
storage
4°C, protect from light
References
[1] Rawls S, et al. Antibiotics, β-Lactam. Encyclopedia of the Neurological Sciences, 2014; 207-209.
Supplier
Hubei widely chemical technology Co., Ltd.
Telephone027-83991130 18627774460
Websitehttp://www.widelychemical.com
Hubei Wanye Zhongcheng Chemical Reagent Co., Ltd.
Telephone 18671296875
Websitehttps://www.wanyezhongcheng.com
Shenzhen Excellent Biomedical Technology Co., Ltd.
Telephone 18318671572
Websitehttps://www.ex-biotech.com/
Jinan Yunding Biotechnology Co., Ltd
Telephone 15662712965
Website
Hunan Revel Biotechnology Co. , Ltd.
Telephone19359985961 19359985961
Websitehttps://www.chemicalbook.com/supplier/25708344/
XiaoGan ShenYuan ChemPharm co,ltd
Telephone 15527768850
Websitehttp://www.farchem.com/
Hangzhou Yuhao Chemical Technology Co., Ltd
Telephone0571-82693216
Websitehttp://www.chemyuhao.com
Wuhan Fortuna Chemical Co., Ltd
Telephone027-59207852 13308628970
Websitehttp://www.fortunachem.cn
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Telephone0755-4000505016 13380397412
Websitehttp://www.phystandard.com.cn
Beijing HuaMeiHuLiBiological Chemical
Telephone010-56205725
Websitehttp://www.huabeibiochem.com/
Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.
Telephone025-66099280 17798518460
Websitehttp://www.aikonchem.com/
Haoyuan Chemexpress Co., Ltd.
Telephone021-58950125
Websitehttp://gb.chemexpress.com.cn
Guangzhou Isun Pharmaceutical Co., Ltd
Telephone020-39119399 18927568969
Websitehttp://www.isunpharm.com
Nanjing Sunlida Biological Technology Co., Ltd.
Telephone025-57798810
Websitehttp://www.sunlidabio.com
GIHI CHEMICALS CO.,LTD
Telephone0086-571-86217390
Websitehttp://www.gihichem.com
Wuhan DKY Technology Co.,Ltd.
Telephone27-81302488 18007166089
Websitehttp://www.wuhandky.com
ChemStrong Scientific Co.,Ltd
Telephone0755-0755-66853366 13670046396
Websitehttp://www.chem-strong.com
Finetech Industry Limited
Telephone027-87465837 19945049750
Websitehttps://www.finetechchem.com/
1of4
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine